Navigation Links
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
Date:8/21/2008

ntinued, "we saw virtually no side effects in the patients treated in phase II trials. Based on our previous trial results, we think Lucanix(R) may lead to a significant advancement in patient care. We look forward to continuing to enroll patients in this very important clinical study."

"We are delighted to have been selected as one of the major centers to test this highly promising immunotherapeutic approach to treating individuals with NSCLC," said Dr. Julian Molina, principal investigator of the STOP Trial at Mayo Clinic in Rochester, Minnesota.

Lucanix(R) consists of four non-small cell lung cancer cell lines that have been genetically engineered to shut off their immune suppressive properties. These cell lines are then modified to block a molecule called transforming growth factor-beta (TGF-beta), which is commonly produced by cancer cells as a cloak against the body's natural immune system. When TGF-beta is blocked, the immune system can mount an anti-tumor response. The results of Phase II testing were published in the October 10, 2006 edition of the Journal of Clinical Oncology.

Studies to test the therapeutic vaccine in other types of cancer are also in progress. "NovaRx remains committed to developing whole cellbased therapeutic vaccines for any form of cancer in which this approach may significantly improve patient outcomes by either curing their disease entirely, or by stabilizing it over the course of their lives," said Justin Murdock, CEO and chairman of the board of NovaRx.

Founded in 1997, NovaRx Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel cell-based therapeutic vaccines for the treatment of cancer. The company's 24,000 square foot headquarters in San Diego, CA, house corporate offices and manufacturing operations. The proprietary core technology upon which Lucanix(R) is based has been exclusively licensed to NovaRx on a worldwide basis. Lucani
'/>"/>

SOURCE NovaRx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
5. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
6. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
7. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
8. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
9. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2015)... -- Current asthma medications, which work by suppressing ... the airways, can stop working over time. A ... Hospital and Harvard Medical School supports a surprising ... nerve endings in the lungs that help drive ... journal Neuron on June 25, the ...
(Date:6/25/2015)... (PRWEB) , ... June 25, 2015 , ... ... Framingham State University will enjoy (8) new chemistry laboratories, each exclusively using filtered ... week, Erlab’s team finished installing the (49) filtered fume hoods needed for their ...
(Date:6/25/2015)... , June 25, 2015  The Galien Awards Committee ... Genome Sciences and Medical Genetics at the University of ... Bono Humanum Award at the ninth annual Prix Galien ...   The Pro Bono Humanum Award recognizes ... the first woman recipient of the award.   ...
(Date:6/25/2015)... June 25, 2015 iAngels ... with Startup Nation,s leading angels and gain access to ... Darya Fuks as Portfolio Manager.  , ,Fuks, a ... lead iAngels, deal flow and due diligence activities for ... all iAngels portfolio companies. An investment banker with deep ...
Breaking Biology Technology:Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 3Former J.P. Morgan Vice President Darya Fuks Joins iAngels 2Former J.P. Morgan Vice President Darya Fuks Joins iAngels 3
... , , , , , ... for amplification. , For a quick overview you can browse ... Although all products will perform in a broad , array ... can be leveraged in your specific applications. This guide is designed to , ...
... , Here are some troubleshooting hints that we have gathered , regarding non-specific bands after PCR reactions: , ... , , , ... , <a , ... , , , ...
... , for routine amplification of up to 3 kb genomic ... , , , , , ... Kit contains 10 vials of 2x concentrated PCR reaction , mix ... detergent, dNTPs) plus water PCR grade (for dilution), sufficient for 100 , ...
Cached Biology Technology:Trouble-shooting: Non-specific bands 2Trouble-shooting: Non-specific bands 3Trouble-shooting: Non-specific bands 4Trouble-shooting: Non-specific bands 5Trouble-shooting: Non-specific bands 6PCR Master 2PCR Master 3
(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/17/2015)... Fla. , June 17, 2015  Crossmatch™, ... today announced that its U.are.U ® 4500 ... Togo,s Eateries, Inc., a ... sandwich chain, to increase security, improve accountability and ... readers enable instant, non-repudiable identity confirmation for employee ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... team led by scientists at the Sainsbury Laboratory in ... plant diseases across different plant families. This breakthrough ... resistance to economically important diseases. Food insecurity is driving ... food we grow, whilst at the same time reducing ...
... decades, scientists have been pursuing a potential new way ... as antimicrobial peptides (AMPs). Now, MIT scientists have recorded ... AMPs, most of which kill by poking holes in ... MIT Professor Angela Belcher modified an existing, extremely sensitive ...
... heart disease, less isn,t always more at least when ... increased risk of heart attack, stroke or death for patients ... low, according to Rhonda Cooper-DeHoff, Pharm.D., an associate professor of ... (Sunday, March 14) at the American College of Cardiology,s 59th ...
Cached Biology News:New defenses deployed against plant diseases 2New microscopy technique offers close-up, real-time view of cellular phenomena 2UF researcher urges caution in reducing blood pressure in patients with diabetes, coronary disease 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... for relax positively and negatively supercoiled DNA in ... , Studying the effects of supercoiling on transcription ... vitro , Determining the degree of supercoiling ... plasmids that differ in length by only one ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: